维兹曼尼亚凝血菌BC99通过调节炎症,神经递质和脂质代谢途径缓解便秘症状:一项随机,双盲,安慰剂控制的试验
Qiuxia Fan1,2,3, Yinyin Gao1, Yiqing Zhou1
1College of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471000, China.
Foods (Basel, Switzerland)
|February 26, 2025
概括
维兹曼尼亚凝血剂BC99显著改善了成年人的便秘症状和生活质量. 这种益生菌还积极调节神经递质,炎症和与肠道健康相关的代谢物.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 临床营养学 临床营养学
背景情况:
- 益生菌因其对胃肠道健康的益处而闻名,特别是对于便秘.
- 便秘影响了相当一部分成年人群,影响了他们的生活质量.
- 确定有效的益生菌菌株用于便秘管理至关重要.
研究的目的:
- 评估*Weizmannia coagulans* BC99在改善成年人便秘症状方面的疗效.
- 调查作用的潜在机制,包括对神经递质,炎症和代谢物的影响.
- 评估BC99对患者生活质量的影响.
主要方法:
- 这是一项随机,双盲,安慰剂对照试验,涉及90名便秘的成年人.
- 一个为期8周的干预期,使用*Weizmannia coagulans* BC99或安慰剂.
- 评估自发性排便的频率,症状得分 (PAC-SYM,PAC-QOL),炎症性细胞因子,神经递质和血清代谢物.
主要成果:
- BC99显著增加了自发排便频率和改善了生活质量得分 (PAC-QOL).
- 在BC99组中,便秘症状严重程度 (PAC-SYM) 显著降低.
- 降低了BC99调节的神经递质 (例如5-HT,BDNF),降低了促炎性细胞因子 (IL-6,IFN-γ),并改变了关键的代谢途径.
结论:
- *Weizmannia coagulans* BC99是有效和安全的缓解成年人的便秘.
- BC99证明了涉及神经递质调节,抗炎作用和代谢途径调节的潜在机制.
- 这些发现支持使用BC99作为一种针对便秘的益生菌干预措施.
相关概念视频
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
923
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
923
Drugs Affecting GI Tract Motility: Other Laxatives
1.6K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.6K
Drugs for Treatment of Diarrhea-Predominant IBS
1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Drugs for Treatment of Constipation-Predominant IBS
1.5K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.5K
Irritable Bowel Syndrome III: Medical and Nursing Management
997
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
997
Irritable Bowel Syndrome
70
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility...
70


